Rare Disease Report

Search results for "quizartinib "

Search Keyword

Published: Dec 05, 2018
www.raredr.com/conferences/ash-2018/jorge-cortes-md-reviews-positive-phase-3-quizartinib-data-aml-treatment
Jorge Cortes, MD, highlights the phase 3 QuANTUM-R trial results and explains their clinical implications for patients with FLT3-ITD-mutated relapsed/refractory acute myeloid leukemia (AML). 
Published: Aug 02, 2018
www.raredr.com/news/fda-grants-breakthrough-therapy-designation-to-relapsedrefractory-flt3itd-aml-treatment
The FDA has granted a breakthrough therapy designation to Daiichi Sankyo Company, Limited’s investigational FLT3 inhibitor, quizartinib, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).
Published: May 08, 2018
www.raredr.com/news/quizartinib-prolongs-survival-aml
Results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib significantly prolongs overall survival compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD mutations.
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.